Actrims Virtual
MSVirtual2020, September 11-13, 2020 actrims Logo

The 8th Joint ACTRIMS-ECTRIMS Meeting, the largest conference focused on Multiple Sclerosis (MS) research, will be held in a virtual format from September 11-13, 2020, with a special encore featuring Late-Breaking News and a COVID-19 Session on September 26.

This virtual conference – MSVirtual2020 – involves world class scientists, clinicians and researchers in the field of multiple sclerosis (MS) from around the world presenting the latest research advances, clinical trial data and outcomes, therapeutic advances, new breakthroughs and new cutting-edge technology in MS.

Media registration will allow you to have access to the full program. We hope you will join us for this virtual conference.

#MSVirtual2020

News Releases Register for a Press Pass to MSVirtual 2020

Meeting News Releases on Newswise

Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Outlines Guidance for Diagnosing Pediatric and Late-Onset Multiple Sclerosis
A new review led by the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) provides guidance on how to diagnose suspected multiple sclerosis (MS) in individuals under 18 and adults 50 years and older.
– Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) | 26-Sep-2024 3:05 PM EDT

Making Connections will be the focus at the ACTRIMS Forum 2025
The Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) is excited to announce its tenth annual Forum, taking place from February 27 to March 1, 2025, at the Palm Beach County Convention Center and the Hilton West Palm...
– Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) | 1-Aug-2024 12:05 PM EDT

National MS Society Awards Dr. Sergio Baranzini the Barancik Prize for Innovation in MS Research
Sergio E. Baranzini, PhD, a geneticist, neuroimmunologist, and data scientist at the University of California, San Francisco, is the winner of this year’s Barancik Prize for Innovation in MS Research.
– Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) | 30-Jan-2024 11:05 AM EST

The ninth annual ACTRIMS Forum will be held Feb. 29 - March 2 in West Palm Beach, Florida.
Breaking Barriers in MS will be the focus at the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum 2024
– Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) | 3-Aug-2023 11:30 AM EDT

Is it MS or Something Else? Updated Guide is Published to Expedite and Uncover the Answer
An international consortium led by ACTRIMS has published detailed updated recommendations for how to distinguish suspected multiple sclerosis from other look-alike disorders. This critical guidance aims to reduce the time spent to confirm an...
– Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) | 19-Jul-2023 2:30 PM EDT

ACTRIMS Forum 2023 themed MS: Going Viral
The Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) annual Forum will be held Feb. 23-25, 2023, in San Diego, California at the Marriott Marquis San Diego Marina. Themed “MS: Going Viral,” the Forum 2023, will...
– Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) | 8-Sep-2022 1:05 PM EDT

ACTRIMS Board Member Dr. Amit Bar-Or Wins Barancik Prize for Innovation in MS Research
The National MS Society announced that Amit Bar-Or, MD, the Melissa and Paul Anderson President’s Distinguished Professor of Neurology at the Perelman School of Medicine at the University of Pennsylvania is this year’s recipient of the Barancik...
– Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) | 17-Feb-2022 4:05 PM EST

Evolution of the Neuroinflammatory Response Over the Clinical Course of MS
Benjamin M. Segal, M.D., The Ohio State University, to present keynote address at ACTRIMS Forum 2021
– Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) | 22-Feb-2021 1:05 PM EST

The Spectrum of Multiple Sclerosis will be the focus at Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) 2021 Forum
Forum Announcement
– Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) | 19-Jan-2021 11:40 AM EST

Q&A with Leaders of MS Virtual 2020 Conference
ACTRIMS MS Virtual 2020 Q&A with Association Leadership
– Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) | 16-Sep-2020 5:10 PM EDT

COVID-19 in persons with multiple sclerosis treated with ocrelizumab: pharmacovigilance update

– Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) | 22-Sep-2020 12:50 PM EDT

First results of the COVID-19 in MS Global Data Sharing Initiative suggest anti-CD20 DMTs are associated with worse COVID-19 outcomes

– Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) | 22-Sep-2020 12:45 PM EDT

Evidence of an Increased Burden of Humoral Autoimmunity in the CSF and plasma of COVID-19 Patients with Comorbid Neurologic Dysfunction
Coronavirus disease 19 (COVID-19) is the most globally impactful pandemic of the past century.
– Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) | 22-Sep-2020 12:10 PM EDT

Comparison of COVID-19 outcomes between racial groups in the COViMS registry

– Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) | 22-Sep-2020 12:05 PM EDT

COVID-19 in people with MS: A large community-based study of the UK MS Register

– Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) | 22-Sep-2020 11:40 AM EDT

Interrupting disease modifying treatment for pregnancy in multiple sclerosis – effect on disease activity and serum neurofilament light chain

– Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) | 22-Sep-2020 11:15 AM EDT

Network analysis identifies gut bacteria associated with multiple sclerosis relapse among pediatric-onset patients

– Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) | 22-Sep-2020 11:05 AM EDT

Brain microstructural and metabolic alterations detected in vivo at the onset of the first demyelinating event

– Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) | 22-Sep-2020 10:30 AM EDT

Neutrophil granulocyte markers in cerebrospinal fluid differentiate NMOSD and anti-MOG antibody associated disease from MS in acute disease phase

– Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) | 22-Sep-2020 10:15 AM EDT

Phase 2 clinical trial evidence that a retinoid-X receptor agonist promotes remyelination in people with relapsing-remitting multiple sclerosis

– Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) | 22-Sep-2020 10:05 AM EDT

More About MEETING

The 8th Joint ACTRIMS-ECTRIMS Meeting, the largest conference focused on Multiple Sclerosis (MS) research, will be held in a virtual format from September 11-13, 2020, with a special encore featuring Late-Breaking News and a COVID-19 Session on September 26.

This virtual conference – MSVirtual2020 – involves world class scientists, clinicians and researchers in the field of multiple sclerosis (MS) from around the world presenting the latest research advances, clinical trial data and outcomes, therapeutic advances, new breakthroughs and new cutting-edge technology in MS.

Media registration will allow you to have access to the full program including plenary sessions, invited speakers and platform presentations, and industry supported satellite symposia. Registered media will also have access to presentations that you may have missed 24 hours after their live presentations.

Newswise will be the host of the MSVirtual2020 NewsRoom that will provide journalists with information about the conference and its program, press releases, and helpful material, as well as links to the program site. It will also host special press events for media-only, providing journalists with an opportunity to speak with the ACTRIMS and ECTRIMS leaders as well late-breaker investigators in interactive Q&A type session. The press managers will be available to furnish interviews with presenters, clinicians and scientists participating in this conference upon request. You can reach out to them anytime with your requests or questions.

Learn More About Us

Media Contacts

Lynn Blenkhorn
[email protected]
(508) 851-0930 (Mobile)

Emily Papp
[email protected]
(203) 240-8446 (Mobile)

ACTRIMS

[email protected]
+ 1 608 310 8960

1818 Parmenter Street, Suite 300
Middleton, Wisconsin 53562
USA

Important Links

Press Events

  • Opening Press Conference with ACTRIMS and ECTRIMS Leaders with Q&A (Media only)
    -- Friday, September 11th @8:00 a.m. ET
  • Virtual Coffee Break with the ACTRIMS President (Media Only)
    -- Provides you with a chance to ask the President questions regarding key presentations, major conference research themes, studies and clinical outcomes, breakthroughs, current challenges and what’s next in MS research, etc.
    -- Sunday, September 13th @ 7:30 a.m.ET
  • Early Availability of Embargoed Late Breaker Abstracts for Media Only
    -- Thursday Morning, September 24th
  • Late-Breaker Press Event – Q&A with Investigators (Media only)
    -- Friday, September 25th @ 9:00 a.m.ET
  • Encore Event: Late Breaker Presentations (Open to all attendees and media)
    -- Saturday, September 26th at 9-10:30
  • Encore Event: Covid-19 and MS Special Session (For all attendees and media)
    -- Saturday, September 26th @ 10:45-12:15

Program at a Glance

Experts

Gallery

Social Feed